Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Frailty as a mortality predictor in older adults with COVID-19: A systematic review and meta-analysis of cohort studies

Ita Daryanti Saragih, MSN, RN.a,#, Shailesh Advani, MD, Ph.D.b,#, Ice Septriani Saragih, MSN, RNc, Ira Suarilah, MSN, RN.d, Irwan Susanto, M.Ed.e, Chia-Ju Lin, PhD, RN.f,*

a Graduate Student, College of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan
b Cancer Prevention and Control Program, Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA and Terasaki Institute of Biomaterial Innovation, Los Angeles, CA, USA
c Assistant Professor, Department of Medical Surgical Nursing, STIKes Santa Elisabeth Medan, Indonesia
d Doctoral student, College of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan
e Assistant Professor, Faculty of Teacher Training and Education, Universitas Darma Agung, Indonesia
f Assistant professor, College of Nursing, Kaohsiung Medical University and Research member, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

ARTICLE INFO

Article history:
Received 27 March 2021
Received in revised form 1 June 2021
Accepted 2 June 2021
Available online 12 June 2021

Keywords:
Older adults
COVID-19
Frailty
Mortality
Meta-analysis

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused the coronavirus diseases 2019 (COVID-19) pandemic, continues to spread rapidly worldwide and is associated with high rates of mortality among older adults, those with comorbidities, and those in poor physiological states. This paper aimed to systematically identify the impact of frailty on overall mortality among older adults with COVID-19. We conducted a systematic review of the literature indexed in 4 databases. A random-effects model with inverse variance-weighted meta-analysis using the odds ratio was used to study the association of frailty levels with clinical outcomes among older adults with COVID-19. Heterogeneity was measured using the $I^2$ statistic and Egger’s test. We identified 22 studies that met our inclusion criteria, including 924,520 total patients. Overall, frailty among older adults was associated with high rates of COVID-19-related mortality compared with non-frail older adults (OR [odds ratio]: 5.76; 95% confidence interval [95% CI]: 3.85/8.61, $I^2$: 40.5%). Our results show that physical limitations, such as those associated with frailty among older adults, are associated with higher rates of COVID-19-related mortality.

© 2021 Elsevier Inc. All rights reserved.

Introduction

The global pandemic associated with coronavirus disease 2019 (COVID-19) was declared a public health emergency by the World Health Organization in March 2020. Since the first case was discovered in Wuhan, China, in late 2019, the pandemic has resulted in more than 102,007,448 cases globally and 2,206,055 deaths, as of January 30, 2021. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative COVID-19 coronavirus, is known to directly invade human extrapulmonary organs and tissues, leading to multiple organ dysfunction. Although COVID-19 impacts people of all ages, this disease shows a predisposition for older adults and those with underlying comorbidities. The risk of infection, viral load, and poor clinical outcomes, including intensive care unit (ICU) admissions, the need for supplemental oxygen, and mortality, remain high, particularly among those with increased age or who have underlying comorbidities.

Frailty is defined as an extreme vulnerability to endogenous and exogenous stressors, which exposes an individual to a higher risk of negative health-related outcomes and commonly impacts older adults. The factors that contribute to frailty syndrome are regularly assessed in geriatric research, and consist of a combination of deficiencies in strength, balance, motor processing, cognition, nutrition, endurance, and physical activity. Frail adults tend to have physical weakness and declining psychological capacity due to multidimensional reductions in physiological function, resulting in adverse health outcomes. Along with aging, frailty in older adults is typically accompanied by...
underlying physiological changes that increase the risk of hospitalization and overall mortality. The measurement of frailty using the Clinical Frailty Scale (CFS) has been used to predict falls, delirium, hospitalization, and mortality among older adults. Prior studies have indicated significant associations between frailty and poor cancer screening outcomes. response to surgery, chemotherapy, and overall mortality and morbidity. Among COVID-19 patients, a study in Italy found a relatively high number of deaths among hospitalized frail older people.

Limited evidence exists regarding frailty as a predictor of COVID-19 infection risk or associated outcomes. Given the high prevalence of frailty among older adults, we conducted a systematic review and meta-analysis to study the impacts of frailty on COVID-19 outcomes.

Material and methods

This study was registered in the International Prospective Register of Systematic Review (PROSPERO): CRD42020209962. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines during the conduct of this systematic review.20

Search strategy

To determine relevant studies, we searched CINAHL, Google Scholar, PubMed (MEDLINE), and Web of Science databases from December 1, 2019, to October 14, 2020, with the help of a health science librarian. We later updated the search on March 17, 2021. The medical subheading (MeSH) terms used to develop our search included: “Frail” AND “older adults” OR “older adults” OR “elderly” OR “older patients” OR “geriatric” AND “COVID 19” OR “coronavirus disease 2019” OR “cov-19” OR “sars-cov-2” OR “coronavirus” OR “Wuhan coronavirus” OR “novel coronavirus” AND “mortality” OR “death” OR “deceased”. We developed the search parameters for one database and later modified the parameters for the other databases (Supplementary Document 1).

Eligibility criteria

To determine the inclusion criteria, the PICOS method (Population, Intervention/issue of interest, Comparison, Outcome, and Study design) was used.21 The following were our eligibility criteria: a) patients with COVID-19 older than 65 years; b) clinical outcomes including mortality, ICU admission, and ventilator use; c) cohort studies, case-control studies, or cross-sectional studies; and d) published in the English language. Studies that were not within the scope of the PICOS criteria or did not provide access to the full text were excluded. Two authors (IDS, ISS) independently screened all relevant abstracts against the inclusion and exclusion criteria. Abstracts were coded as yes or no based on each individual’s judgment against the PICOS criteria for full-text abstraction. Discrepancies were resolved through discussion and mutual consensus.

Data extraction

Two authors (IDS, SOB) independently performed the comprehensive abstraction of key data points, including author names, country of study implementation, sample size, death (total number, %, sex), number of patients who required a ventilator or were admitted to the ICU, survival time, demographics, frailty definition, tools used to measure frailty, cutoffs used to define frailty, body mass index, frailty levels, and other relevant components.

Quality assessment

Initially, we assessed the study design of the selected studies using a methodological quality assessment scale to minimize the risk of bias.22-23 For each reviewed source, we used the Joanna Briggs Institute (JBI) assessment tool24 for cohort studies to assess the level of evidence present. The 12-item JBI Critical Appraisal Checklist for cohort studies, which was updated and released in 2020, was used to assess the overall methodological quality, which classified overall quality as high, moderate, low, and very low.25-28 Each of the 12 items was scored as 0 (high risk of bias) or 1 (low risk of bias), resulting in a total score ranging from 0 to 12, with 10–12 points categorized as high quality, 7–9 points categorized as moderate quality, 4–6 points categorized as low quality, and 0–3 points categorized as very low quality.

Statistical analysis

We calculated the pooled prevalence of mortality among frail and non-frail older adults with COVID-19 using a random-effects model with inverse variance weighting. We calculated pooled odds ratio (OR) of mortality among frail older adults relative to that of non-frail adults. Funnel plots and forest plots were generated for our analysis. The Egger’s test was assessed to measure publication bias due to small sample size.29,30 We determined the heterogeneity of each variable assessed by a pooled estimate using $I^2$ with a random-effects model; $I^2$ values of 25%-49% indicated low heterogeneity, 50%-74% indicated moderate heterogeneity, and >75% indicated high heterogeneity.31 $P < 0.05$ was considered significant. All statistical analyses were conducted using Stata 15.0.

Results

Study selection

The initial search retrieved 98 articles. Using EndNote software, 36 studies were removed due to duplication. We screened a total of 62 publications during the title and abstract screening, among which 32 were deemed ineligible because they did not meet the scope of the PICOS criteria, as follows: the study included a population with COVID-19 younger than 65 years (n = 13); the study was not an original article (n = 6); the study did not provide outcomes for mortality, ICU admission, or ventilator use among frail vs. non-frail groups (n = 8); and the study was not in the English language (n = 5). A total of 30 full-text sources were screened against the full-text eligibility criteria. A total of 1 additional study was removed because it was not an original article, 2 studies were removed because the population did not include patients with COVID-19, and 5 studies were removed because they did not provide outcome results for mortality among frail vs. non-frail groups.

Finally, 22 sources were included in our final analysis.32-53 The process used to select study sources is presented in Fig. 1 through a PRISMA flow diagram.

Studies characteristics

Nine studies were conducted in the UK, 2 studies were conducted in Italy, and 1 study each was conducted in Australia, the Netherlands, both the UK and Italy, Belgium, Turkey, Germany, Switzerland, Ireland, Brazil, Sweden, and Europe (11 countries). A total of 924,520 participants were confirmed as COVID-19-positive across the 22 included studies were included in our final analysis. The majority of participants were women (79%). The ages of our participants ranged from 67.5 – 86.3 years. Of the 19 that used CFS criteria to define frailty, 16 used the following categorization: CFS 1 – 3 as non-frail vs. CFS 4 – 9 as frail. The other 3 studies that used CFS criteria categorized CFS

...
1–4 as non-frail and CFS 5–9 as frail. Two studies used the frailty phenotype to define frailty, with scores of 0 categorized as non-frail and 1–5 categorized as frail. The last study used the Hospital Frailty Risk Score (HFRS) to define frailty, with HFRS < 5 defined as non-frail and HFRS ≥ 5 defined as frail. The follow-up periods ranged from 30 days to 105 days. A summary of the included studies is provided in Table 1.

Meta-analysis of 13 selected studies

Mortality among frail older adults with COVID-19

A total of 7 studies were analyzed to estimate the prevalence of mortality among frail and non-frail adults with COVID-19 and the impact of frailty on overall COVID-19-related mortality.35,40,44,45,49,52,54 The pooled prevalence of mortality among frail older adults confirmed as COVID-19-positive was higher than that among non-frail older adults (44% vs. 13%; Figs. 3–4). The pooled OR for mortality among frail older adults compared with non-frail older adults was 5.76 (95% confidence interval [CI]: 3.85–8.61; Fig. 2). Our analysis showed the presence of low heterogeneity ($I^2 = 40.5\%$, $p < 0.121$). Egger’s test was non-significant ($t = -0.59$, $p = 0.583$).

Quality assessment for methodology

The JBI tool for cohort studies was used to analyze the 22 articles included in this study. All included studies were assessed with high methodological quality. In general, the strategies used to address incomplete follow-up were responsible for lower scores. One limitation in our study was the observation of asymmetry for all outcomes analyzed, indicating the presence of publication bias due to small sample size, based on the funnel plot visualization (Supplementary Document 2, Figure 5). However, Egger’s regression test confirmed that the influence of publication bias was small. A summary of the quality assessments is presented in Table 2.

Discussion

This systematic review and meta-analysis included 924,520 patients from a total of 22 studies, with the aim of assessing the aggregate impact of frailty on clinical outcomes among older adults with COVID-19. We found that the pooled prevalence of mortality among frail older adults with COVID-19 was 44%, which was higher than that of their non-frail counterparts and was associated with an overall increase in mortality odds among frail older adults with COVID-19. This finding emphasizes that in addition to underlying comorbidity profiles, frailty remains an important predictor of overall mortality.

We found that frail older adults had higher rates of mortality associated with COVID-19 compared with their non-frail counterparts. COVID-19 continues to impact people of older age with underlying comorbidities. Those with severe COVID-19 infections and lung...
Table 1
Summary of selected studies on frailty as predictor of mortality among older adults with COVID-19

| No | Author/year          | Location | Study design | Total Sample | Men | Age | Study setting | Follow period (days) | Frailty criteria | Frailty outcome | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | Ventilators use |
|----|----------------------|----------|--------------|--------------|-----|-----|--------------|---------------------|------------------|-----------------|---------|---------|---------|---------|---------|-----------------|
| 1  | (Alsahab et al., 2021) | UK       | Cohort study | 4676         | 2114  | 74 | 0 (0) | 4676 (100) | Study period | CFS    | Frail | 2069 (44) | 3012 (64) | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 2  | (Ave, Woodrow, Ogliari, & Harven, 2020) | UK       | Cohort study | 677          | 366   | 81.1 | 0 (0) | 667 (100) | Study period | CFS    | Frail | 97 (14)  | 567 (84)  | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 3  | (Blommaert et al., 2021) | Netherlands | Cohort study | 1376         | 830   | 78 | 0 (0) | 1376 (100) | Study period | CFS    | Frail | 515 (37) | 601 (44)  | NA       | NA       | 120 (23) | 23 (4)   | NA       | Frail                  |
| 4  | (Carter et al., 2020) | UK       | Cohort study | 1564         | 903   | ≥65 | 0 (0) | 1564 (100) | Study period | CFS    | Frail | 91 (6)   | 1468 (93) | 7 (8)    | 415 (28) | NA       | NA       | NA       | Frail                  |
| 5  | (Chinadurai et al., 2020) | UK       | Cohort study | 215          | 133   | 74 | 0 (0) | 215 (100) | Study period | CFS    | Frail | 105 (49) | 110 (51)  | 17 (16)  | 69 (63)  | NA       | NA       | NA       | Frail                  |
| 6  | (Cobos-Siès et al., 2020) | Italy    | Cohort study | 128          | 73    | 84 | 0 (0) | 128 (100) | Study period | CFS    | Frail | 39 (30)  | 89 (70)   | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 7  | (Darvall et al., 2020) | Australia | Cohort study | 5607         | 3041  | 65 | 0 (0) | 5607 (100) | Study period | CFS    | Frail | 3755 (67) | 1852 (33) | NA       | NA       | 122 (3)  | 336 (18) | NA       | Frail                  |
| 8  | (Fagard et al., 2021) | Belgium  | Cohort study | 105          | 55    | 82 | 0 (0) | 105 (100) | Study period | CFS    | Frail | 43       | 62        | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 9  | (Hewitt et al., 2020) | UK and Italy | Cohort study | 1564         | 903   | ≥65 | 0 (0) | 1564 (100) | Study period | CFS    | Frail | 91 (6)   | 1468 (93) | 7 (8)    | 415 (28) | NA       | NA       | NA       | Frail                  |
| 10 | (Ho et al., 2020) | UK       | Cohort study | 502000       | 210019 | ≥65 | 0 (0) | 502000 (100) | Study period | Frail  | Score 0 | 178687 (36) | 186401 (37) | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 11 | (Kundi et al., 2020) | Turkey   | Cohort study | 18234        | 8498  | 74.1| 0 (0) | 18234 (100) | Study period | HFRS   | Frail | 5814 (32) | 12420 (68) | NA       | 975 (17) | 4146 (33) | 650 (11) | 777 (7)  | Frail                  |
| 12 | (Labenz et al., 2020) | Germany  | Cohort study | 42           | 29    | 67.5| 0 (0) | 42 (100)  | Study period | CFS    | Frail | 28 (66)  | 14 (33)   | NA       | NA       | 6 (21)  | 6 (43)   | Frail                  |
| 13 | (Marengronzi et al., 2021) | Italy    | Cohort study | 165          | 100   | 69.3| 0 (0) | 165 (100) | Study period | CFS    | Frail | 142 (86) | 20 (12)   | 25 (18)  | 15 (75)  | NA       | NA       | NA       | Frail                  |
| 14 | (Mendes et al., 2020) | Switzerland | Cohort study | 235          | 102   | 88.3| 0 (0) | 235 (100) | Study period | CFS    | Frail | 50 (21)  | 185 (79)  | 5 (10)   | 71 (38)  | NA       | NA       | NA       | Frail                  |
| 15 | (Monleyen et al., 2020) | Ireland  | Cohort study | 69           | 40    | 79 | 0 (0) | 69 (100)  | Study period | CFS    | Frail | 25 (30)  | 44 (54)   | NA       | NA       | 18 (72) | 25 (57)  | Frail                  |
| 16 | (Petermann-Rocha et al., 2020) | UK       | Cohort study | 383845       | 172535 | 67.1| 0 (0) | 383845 (100) | Study period | Frail  | Score 0 | 170964 (45) | 77668 (20) | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 17 | (Poco et al., 2021) | Brazil   | Cohort study | 71100        | 405   | 66 | 0 (0) | 711 (100) | Study period | CFS    | Frail | 530 (75) | 181 (25)  | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 18 | (Osaiofo et al., 2020) | UK       | Cohort study | 214          | 120   | 80.3| 0 (0) | 214 (100) | Study period | CFS    | Frail | 72 (34)  | 142 (66)  | 15 (21)  | 59 (42)  | NA       | NA       | NA       | Frail                  |
| 19 | (Owen et al., 2020) | UK       | Cohort study | 1071         | 154   | 79.7| 0 (0) | 285 (100) | Study period | CFS    | Frail | 90 (8)   | 402 (43)  | NA       | NA       | NA       | NA       | NA       | Frail                  |
| 20 | (Sablerolles et al., 2021) | Europe   | Cohort study | 1338         | 780   | ≥65 | 0 (0) | 1338 (100) | Study period | CFS    | Frail | 585 (44) | 753 (56)  | NA       | NA       | 166 (28) | 160 (21) | NA       | Frail                  |
| 21 | (Tehrani, Killander, Astrand, Jakobsson, & Gille-Johnson, 2020) | Sweden  | Cohort study | 255          | 150   | 81 | 0 (0) | 255 (100) | Study period | CFS    | Frail | 38 (15)  | 115 (45)  | 5 (13)   | 58 (50)  | NA       | NA       | NA       | Frail                  |
| 22 | (Vlachos et al., 2021) | UK       | Cohort study | 429          | 234   | ≥65 | 0 (0) | 429 (100) | Study period | CFS    | Frail | 259 (60) | 170 (40)  | NA       | 62 (24)  | 14 (8)   | NA       | Frail                  |

CFS: Clinical Frailty Scale; HFRS: Hospital Frailty Risk Score; NA: Not available.
manifestations tend to present with shortness of breath, low oxygen saturation, abnormal lung function tests, and abnormal lung computed tomography (CT) imaging that continues to persist weeks to months after the infection subsides. For those who experience a severe disease course, treatment and support with supplemental oxygen and ventilator use can sustain lung function and maintain adequate circulation. David Spiegelhalter stated that among people with comorbidities, “getting COVID-19 is like packing a year’s worth of risk into a week or two.” COVID-19 infection has been associated with the occurrence of cytokine storm, hyper-inflammation, and
respiratory distress, which involves the recruitment of cytokines and can initiate downstream processes, including hypercoagulation, thrombosis, and disseminated-intravascular coagulation. These processes can become exaggerated among those who have weakened immune systems, underlying comorbidities, or frailty.

Frailty represents a multidimensional concept associated with declines in multiple aspects, including physicality, functionality, cognition, and sociality. Frailty and COVID-19 share similar underlying biological mechanisms, including the role of the renin–angiotensin system (RAS) as an entry mechanism for SARS-CoV-2. In frailty, the RAS plays a role in the regulation of the balance between the proinflammatory and anti-inflammatory effects of the angiotensin (Ang) II type 1 receptor and the Ang II type 2 receptor, respectively, and disruption can result in increased inflammation, oxidative stress, and apoptosis, leading to inflammaging. Frailty has also been associated with poor post-vaccination immune response and increased rates of influenza-like illness and laboratory-confirmed influenza infections, highlighting similar underlying mechanisms associated with COVID-19-related outcomes among frail individuals. Frail individuals tend to present with sarcopenia, loss of muscle mass, and weak muscle functions, including the respiratory muscles, resulting in a synergistic effect on respiratory function when combined with the pneumonia progression associated with COVID-19.

Most of the included studies (19/22) in our analyses used the CFS to predict mortality among older adults with COVID-19, as shown in Table 1. The use of CFS was suggested as a prognostic indicator of survival and predicted functional decline among older adults with COVID-19. A continuing debate exists regarding the assessment of frailty, in addition to age and comorbidity burden, when rationing resources during the COVID-19 pandemic. The authors stress that admission to acute medical care units and the allocation of resources should consider age, comorbidity status, and frailty, as measured by the CFS, when performing clinical decision-making among patients with COVID-19. One original analyzed age, comorbidities, and frailty to predict death among older adults infected with COVID-19 who required hospitalization and found that CFS was the strongest independent predictor of fatal outcomes among older adults with COVID-19 compared with age and comorbidities. The UK National Institute for Health and Care Excellence (NICE) and the guidelines for the German Society of Intensive Care have both endorsed the use of frailty assessment as an important factor for resource allocation. We found that frail older adults were more likely to require ICU admission and ventilator use when infected with COVID-19, based on the pooled analysis.

One of the strengths of the current study is that this study represents one of the first meta-analyses aimed at estimating the impacts of frailty on COVID-19 outcomes, including mortality, ICU admission, and ventilator use. An important limitation of our study involves a lack of data on clinical outcomes across all, the use of a gold standard for the measurement of frailty, and outcomes reported across categories of sex, age, and other predictors. Moreover, the screening focused only on articles published in the English language; therefore, some relevant studies published in other languages may have been omitted.

Our study further highlights the need to pay special attention to older adults who are frail or have physical limitations. We believe that this study is the first review to focus on frailty as a predictor of death among older adults infected with COVID-19. Given the multidimensional relationship among age, multimorbidity, and frailty, and the impacts of these factors on biological reserves and the immune system, further studies should provide a comprehensive assessment of the mechanisms underlying poor outcomes among frail older adults with COVID-19.
| No | JBI checklist question | (Alsahab et al., 2021) | (Aw, Woodrow, Oghiari, & Harwood, 2020) | (Blomaard et al., 2021) | (Carter et al., 2020) | (Chinnadurai et al., 2020) | (Cobos-Siles et al., 2020) | (Darvall et al., 2020) |
|----|------------------------|------------------------|---------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| 1  | Were the two groups similar and recruited from the same population? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2  | Were the exposures measured similarly to assign people? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3  | to both exposed and unexposed groups? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4  | Was the exposure measured in a valid and reliable way? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5  | Were confounding factors identified? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6  | Were strategies to deal with confounding factors stated? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7  | Were the groups/participants free of the outcome at the start of the study (or at the moment exposure)? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8  | Were the outcomes measured in a valid and reliable way? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9  | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 10 | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11 | Were strategies to address incomplete follow up utilized? | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | Was appropriate statistical analysis used? Overall Appraisal | 1 | Include: 11 | Include: 11 | Include: 11 | Include: 11 | Include: 11 | Include: 11 |
| Level of evidence | No JBI checklist question | Include: 3.b cohort study (Fagard et al., 2021) | Include: 3.b cohort study (Hewitt et al., 2020) | Include: 3.b cohort study (Ho et al., 2020) | Include: 3.b cohort study (Kundi et al., 2020) | Include: 3.b cohort study (Labenz et al., 2020) | Include: 3.b cohort study (Marengoni et al., 2021) | Include: 3.b cohort study |
| 1  | Were the two groups similar and recruited from the same population? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2  | Were the exposures measured similarly to assign people? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3  | to both exposed and unexposed groups? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4  | Was the exposure measured in a valid and reliable way? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5  | Were confounding factors identified? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6  | Were strategies to deal with confounding factors stated? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7  | Were the groups/participants free of the outcome at the start of the study (or at the moment exposure)? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8  | Were the outcomes measured in a valid and reliable way? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9  | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 10 | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11 | Were strategies to address incomplete follow up utilized? | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | Was appropriate statistical analysis used? Overall Appraisal | 1 | Include: 11 | Include: 11 | Include: 11 | Include: 11 | Include: 11 | Include: 11 |
| No | JBI checklist question                                                                 | (Alsahab et al., 2021) | (Aw, Woodrow, Ogliari, & Harwood, 2020) | (Blomsaa et al., 2021) | (Carter et al., 2020) | (Chinnadurai et al., 2020) | (Cobos-Siles et al., 2020) | (Darvall et al., 2020) |
|----|----------------------------------------------------------------------------------------|------------------------|-----------------------------------------|------------------------|------------------------|-----------------------------|-----------------------------|------------------------|
|    | Overall Appraisal                                                                      | Include: 11            | Include: 11                             | Include: 11            | Include: 11            | Include: 11                 | Include: 11                 | Include: 11             |
|    | Level of evidence                                                                       | Exclude: 1             | Exclude: 1                              | Exclude: 1             | Exclude: 1             | Exclude: 1                  | Exclude: 1                  | Exclude: 1             |
|    | JBI checklist question                                                                  | 3.b cohort study       | 3.b cohort study                        | 3.b cohort study       | 3.b cohort study       | 3.b cohort study            | 3.b cohort study            | 3.b cohort study       |
| 1  | Were the two groups similar and recruited from the same population?                     | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 2  | Were the exposures measured similarly to assign people?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 3  | Were the exposures measured similarly to assign people?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 4  | Was the exposure measured in a valid and reliable way?                                   | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 5  | Were confounding factors identified?                                                     | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 6  | Were strategies to deal with confounding factors stated?                                 | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 7  | Were the groups/ participants free of the outcome at the start of the study (or at the moment exposure)? | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 8  | Were the outcomes measured in a valid and reliable way?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 9  | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 10 | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 11 | Were strategies to address incomplete follow up utilized?                                | 0                      | 0                                       | 0                      | 0                      | 0                           | 0                           | 0                      |
| 12 | Was appropriate statistical analysis used?                                               | Include: 11            | Include: 11                             | Include: 11            | Include: 11            | Include: 11                 | Include: 11                 | Include: 11            |
|    | Overall Appraisal                                                                      | Exclude: 1             | Exclude: 1                              | Exclude: 1             | Exclude: 1             | Exclude: 1                  | Exclude: 1                  | Exclude: 1             |
|    | Level of evidence                                                                       | 3.b cohort study       | 3.b cohort study                        | 3.b cohort study       | 3.b cohort study       | 3.b cohort study            | 3.b cohort study            | 3.b cohort study       |
|    | JBI checklist question                                                                  | (Sablerolles et al., 2021) | (Tehrani, Killander, Astrand, Jakobsson, & Gilles-Johnson, 2021) | (Vlachos et al., 2021) | (Vlachos et al., 2021) | (Vlachos et al., 2021)     | (Vlachos et al., 2021)     | (Vlachos et al., 2021) |
| 1  | Were the two groups similar and recruited from the same population?                     | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 2  | Were the exposures measured similarly to assign people?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 3  | Were the exposures measured similarly to assign people?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 4  | Was the exposure measured in a valid and reliable way?                                   | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 5  | Were confounding factors identified?                                                     | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 6  | Were strategies to deal with confounding factors stated?                                 | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 7  | Were the groups/ participants free of the outcome at the start of the study (or at the moment exposure)? | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 8  | Were the outcomes measured in a valid and reliable way?                                  | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
| 9  | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1                      | 1                                       | 1                      | 1                      | 1                           | 1                           | 1                      |
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations of Competing Interest
None.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.gerinurse.2021.06.003.

References
1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–160.
2. Meter W. COVID-19 coronavirus pandemic 2020.
3. Henry BM, de Oliveira LHHS, Benoit S, Pleyers M, Lipi C. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58:1021–1028.
4. Center for Disease Control Prevention. COVID-19 guidance for older adults. Division of Population Health ncdfdp.org. USA: CDC; 2020.
5. Magleby R, Westblad LF, Trzeciak A, et al. Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2020.
6. Cesari M, Prince M, Thiagagaran JA, et al. Frailty: an emerging public health priority. J Am Med Dir Assoc. 2016;17:188–192.
7. WHO. World Report on Ageing and Health. World Health Organization; 2015.
8. Raggi PM, Mulazzani B, Gobbi C, Gobbi B. The role of frailty in predicting mortality and readmission in older adults in acute care wards: a prospective study. BMC Med. 2020;18:274.
9. D’Adamo H, Yoshikawa T, Ouslander JG. Coronavirus disease 2019 in geriatrics and long-term care: the ABCDs of COVID-19. J Am Geriatr Soc. 2020;68:912–917.
10. De Smet R, Mellaerts B, Vandewinckele H, et al. Frailty and mortality in hospitalized older adults with COVID-19: a retrospective observational study. J Am Med Dir Assoc. 2020;21:928–932.e921.
11. Hao Q, Sun X, Yang M, Dong B, Yang M, Wei Y. The role of frailty in predicting mortality and readmission in older adults in acute care wards: a prospective study. J Am Med Dir Assoc. 2019;20:921.
12. Hao Q, Zhou L, Dong B, Yang M, Dong B, Wei Y. The role of frailty in predicting mortality and readmission in older adults in acute care wards: a prospective study. J Am Med Dir Assoc. 2019;20:9:1207.
13. Salminen M, Viljanen A, Eloranta S, et al. Frailty and mortality: an 18-year follow-up study among Finnish community-dwelling older people. Aging Clin Exp Res. 2019.
14. Walter LC, Eng C, Covinsky KE. Screening mammography for frail older women: what are the burdens? J Gen Intern Med. 2001;16:779–784.
15. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210:901–908.
16. Crow RS, Lohman MC, Titus AJ, et al. Mortality risk along the frailty spectrum: data from the national health and nutrition examination survey 1999 to 2004. J Am Geriatr Soc. 2018;66:496–502.
17. Abbatecola AM, Antonelli-Incalzi R. Editorial: COVID-19 spiraling of frailty in older Italian patients. J Nutr Health Aging. 2020;24:453–455.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000100.
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement. Update of explanation and elaboration. PLoS Med. 2009;6: e1000100.
Kundi H, Cetin EHO, Canpolat U, et al. The role of frailty on adverse outcomes in older patients with COVID-19: the COVIDAge study. *J Am Med Dir Assoc*. 2020;21:1546–1554, e1543.

Moloney E, Eustace J, O’Caoimh R, et al. Frailty, *COVID-19* Disease Severity and Outcome Among Hospitalised Older Adults. 2020.

Petersmann-Rocha F, Hanlon P, Gray SR, et al. Comparison of two different frailty measurements and risk of hospitalisation or death from *COVID-19*: findings from UK Biobank. *BMC Med*. 2020;18:1–9.

Poco PCE, Aliberti MJR, Dias MB, et al. Divergent: age, frailty, and atypical presentations of *COVID-19* in hospitalized patients. *J Gerontol: Series A*. 2021;76:e446–e451.

Osafor CN, Davidson C, Mackett AJ, et al. 2020.

Owen RK, Conroy SP, Taub N, et al. Comparing associations between frailty and mortality in hospitalised older adults with or without *COVID-19* infection: a retrospective observational study using electronic health records. *Age Aging*. 2020.

Sablerolles RSG, Lafeber M, van Kempen JAL, et al. Association between Clinical Frailty Scale score and hospital mortality in adult patients with *COVID-19* (COMET): an international, multicentre, retrospective, observational cohort study. *Lancet Healthy Longevity*. 2021;2:e165–e170.

Tehrani S, Killander A, Astrand P, Jakobsson J, Gille-Johnson P. Risk factors for mortality in adult *COVID-19* patients; frailty predicts fatal outcome in older patients. *Int J Infect Dis*. 2020.

Vlachos S, Wong A, Metaxa V, et al. Hospital mortality and resource implications of hospitalisation with *COVID-19* in London, UK: a prospective cohort study. *Crit Care Res Pract*. 2021;2021.

Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief predictors of mortality in *COVID-19* patients admitted to an acute medical unit in a secondary care setting- a cohort study. *BMC Geriatrics*. 2020;20:409.

Cobos-Siles M, Cubero-Morais P, Arroyo-Jimenez I, et al. Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events. *Intern Emerg Med*. 2020.

Darvall JN, Bellomo R, Bailey M, et al. Frailty and outcomes from pneumonia in critical illness: a population-based cohort study. *Irr J Anaesth*. 2020;125:730–738.

Fagard K, Gielen E, Deschodt M, Devriendt E, Flamaing J. Risk factors for severe *COVID-19* disease and death in patients aged 70 and over: a retrospective observational cohort study. *Acta Clin Belg*. 2021;1–8.

Fagard K, Gielen E, Deschodt M, Devriendt E, Flamaing J. Risk factors for severe *COVID-19* disease and death in patients aged 70 and over: a retrospective observational cohort study. *Acta Clin Belg*. 2021;1–8.

Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with *COVID-19* (COPE): a multicentre, European, observational cohort study. *The Lancet Public Health*. 2020;5:e444–e451.

Ho FK, Petersmann-Rocha F, Gray SR, et al. Is older age associated with *COVID-19* mortality in the absence of other risk factors? General population cohort study of 470,034 participants. *PLOS ONE*. 2020;15:e0241824.

Kundi H, Cetin EHO, Canpolat U, et al. The role of frailty on adverse outcomes among older patients with *COVID-19*. *J Infect*. 2020.

Labezn G, Kremers WM, Schattenberg JM, et al. Clinical frailty scale for risk stratification in patients with SARS-CoV-2 infection. *J Investig Med*. 2020;68:1199–1202.

Marenzoni A, Zucchelli A, Vetran D, et al. Beyond chronological age: frailty and multimorbidity predict in-hospital mortality in patients with coronavirus disease 2019. *J Gerontol: Series A*. 2021;76:e38–e45.